Century Therapeutics, Inc. (IPSC) vs ARS Pharmaceuticals, Inc. (SPRY)

Century Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Century Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are of similar size ($273.4M and $263.5M). Century Therapeutics, Inc. grew revenue faster over the last twelve months: 8,286.7% against −14.5%. Across the 14 metrics below, Century Therapeutics, Inc. leads on 9 and ARS Pharmaceuticals, Inc. on 5.

Valuation

Metric IPSC SPRY Biotechnology median
P/E n/m n/m 10.60
P/S 3.03 2.29 9.40
P/B 1.50 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1.99 2.57 9.02
Earnings yield (55.03%) (71.89%) (32.88%)
Free cash flow yield (25.31%) (70.96%) (23.13%)

Profitability

Metric IPSC SPRY Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 0.00% (161.50%) 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% (149.89%) 0.00%
Return on equity (49.65%) 0.00% (51.96%)
Return on assets (38.41%) 0.00% (46.06%)
Return on invested capital (64.92%) 0.00% 0.00%

Growth

Metric IPSC SPRY Biotechnology median
Revenue growth (TTM) 8,286.72% (14.45%) 6.76%
EPS growth (last fiscal year) 91.30% (2,275.00%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IPSC SPRY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.28 3.25 4.97
Net debt to EBITDA 17.95 0.42 1.01

Dividend

Metric IPSC SPRY Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IPSC SPRY Biotechnology median
Market cap 273.43m 263.53m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack